Supplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
Authors:Crescens Tiu, Wing Yau, Diogo Silva et al.
Supplementary Figure 9 from Targeting the NAD<sup>+</sup> Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells
Bruce Chang-Gu, Tuvshintugs Baljinnyam et al. - Unknown
Supplementary Table S2 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
Marie-Anne Goyette, Christopher Graser et al. - Unknown
Supplementary Table S6 from <i>Helicobacter pylori</i> Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis
Data from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies
Marie-Anne Goyette, Christopher Graser et al. - Unknown